Metaclazepam[1] (marketed under the brand name Talis) is a drug which is a
benzodiazepine derivative.[2][3] It is a relatively selective
anxiolytic with less
sedative or
muscle relaxant properties than other benzodiazepines such as
diazepam or
bromazepam.[4] It has an
active metaboliteN-desmethylmetaclazepam, which is the main
metabolite of metaclazepam.[5] There is no significant difference in metabolism between younger and older individuals.[6]
Metaclazepam is slightly more effective as an anxiolytic than
bromazepam,[7] or
diazepam,[8] with a 15 mg dose of metaclazepam equivalent to 4 mg of bromazepam.[9] Metaclazepam can interact with alcohol producing additive sedative-hypnotic effects.[6][10]Fatigue is a common side effect from metaclazepam at high doses.[11] Small amounts of metaclazepam as well as its metabolites enter into human
breast milk.[12]
^Borchers F, Achtert G, Hausleiter HJ, Zeugner H (1984). "Metabolism and pharmacokinetics of metaclazepam (Talis), Part III: Determination of the chemical structure of metabolites in dogs, rabbits and men". European Journal of Drug Metabolism and Pharmacokinetics. 9 (4): 325–46.
doi:
10.1007/bf03189684.
PMID6532806.
S2CID12290664.
^Althaus W, Block J, Förster A, Kühnhold M, Meister D, Wischniewski M (September 1986). "Analytical profile of metaclazepam". Arzneimittel-Forschung. 36 (9): 1302–6.
PMID3790179.
^Buschmann G, Kühl UG, Rohte O (1985). "General pharmacology of the anxiolytic compound metaclazepam in comparison to other benzodiazepines". Arzneimittel-Forschung. 35 (11): 1643–55.
PMID2868732.
^Gielsdorf W, Molz KH, Hausleiter HJ, Achtert G, Philipp P (1986). "Pharmacokinetic profile of metaclazepam (Talis), a new 1.4-benzodiazepine. Influence of different dosage regimens on the pharmacokinetic profile of metaclazepam and its main metabolite under steady-state conditions". European Journal of Drug Metabolism and Pharmacokinetics. 11 (3): 205–10.
doi:
10.1007/bf03189848.
PMID3816876.
S2CID8493668.
^
abMolz KH, Gielsdorf W, Rasper J, Jaeger H, Hausleiter HJ, Achtert G, Philipp P (1985). "Comparison of the pharmacokinetic profile of metaclazepam in old and young volunteers". European Journal of Clinical Pharmacology. 29 (2): 247–9.
doi:
10.1007/bf00547431.
PMID4076323.
S2CID8017809.
^Laakmann G, Blaschke D, Hippius H, Schewe S (May 1989). "Double-blind study of metaclazepam versus diazepam treatment of outpatients with anxiety syndrome". Pharmacopsychiatry. 22 (3): 120–5.
doi:
10.1055/s-2007-1014593.
PMID2568645.
^Marano P, Patti F, Nicoletti F (1988). "Controlled study on the anxiolytic activity of a newly-developed benzodiazepine, metaclazepam". Current Medical Research and Opinion. 11 (1): 41–4.
doi:
10.1185/03007998809111129.
PMID2898320.
^Schmidt V (1983). "[Experimental studies on the interaction of alcohol and metaclazepam]". Beiträge zur Gerichtlichen Medizin. 41: 413–7.
PMID6639614.
^Laakmann G, Blaschke D, Hippius H, Schewe S (May 1988). "Double-blind randomized trial of the benzodiazepine derivative metaclazepam as compared with placebo treatment of outpatients with anxiety syndromes". Pharmacopsychiatry. 21 (3): 136–43.
doi:
10.1055/s-2007-1014665.
PMID2900514.
^Schotter A, Müller R, Günther C, Hausleiter HJ, Achtert G (November 1989). "Transfer of metaclazepam and its metabolites into breast milk". Arzneimittel-Forschung. 39 (11): 1468–70.
PMID2575907.